60 Degrees Pharmaceuticals, Inc. filed a current report with the SEC on October 27, 2026, announcing clinical improvement and negative PCR results in all completed patients enrolled in its expanded access Babesiosis study.

Key Highlights

  • Clinical outcome: The company announced clinical improvement and negative PCR results in all completed expanded access Babesiosis study patients, according to the filing.
  • Report date: The earliest event reported is October 27, 2026, the same date the filing was signed.
  • Signatory: Geoffrey Dow, Chief Executive Officer and President, signed the report on behalf of 60 Degrees Pharmaceuticals, Inc.
  • Exchange and ticker: Common Stock is listed on NASDAQ:SXTP; warrants trade under the symbol SXTPW on the same exchange.
  • Emerging growth company: The registrant identified itself as an emerging growth company under applicable SEC definitions.

60 Degrees Pharmaceuticals Discloses Babesiosis Study Patient Outcomes

60 Degrees Pharmaceuticals, Inc., a Delaware-incorporated pharmaceutical company headquartered at 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C., disclosed on October 27, 2026, that it issued a press release reporting outcomes from its expanded access Babesiosis study. According to the filing, the company observed clinical improvement and negative PCR results in all patients who had completed the study at the time of the announcement. The full text of the press release was attached as Exhibit 99.1 to the current report and incorporated by reference.

The filing was made under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). Babesiosis is a parasitic disease, and the expanded access designation indicates that the study enrolled patients outside of a standard clinical trial framework. The company's common stock trades on NASDAQ:SXTP, with a par value of $0.0001 per share, and its warrants, each exercisable to purchase one share of common stock, trade under the symbol SXTPW on The Nasdaq Stock Market LLC. The registrant holds Commission File Number 001-41719 and IRS Employer Identification Number 45-2406880.

What Was Disclosed

60 Degrees Pharmaceuticals reported, via a current report dated October 27, 2026, that all completed patients in its expanded access Babesiosis study showed clinical improvement and negative PCR results, as detailed in an attached press release (Exhibit 99.1).